Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the ...
Seeking Alpha

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and ...
News Medical

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

Albumedix Ltd, Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14 th March 2023, announce that Recombumin ® is a ...
Nature

Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
BioWorld

PAT-101, a new recombinant human albumin-conjugated urate oxidase with efficacy in vivo

Proabtech Co. Ltd. investigators have published findings from the preclinical characterization of PAT-101, a novel recombinant human albumin (rHA)-conjugated urate oxidase (Uox) variant, being ...